专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20070259887A1 INHIBITORS OF POLYQ-AGGREGATION 审中-公开
标题翻译：聚氨酯抑制剂
公开(公告)号：US20070259887A1
公开(公告)日：2007-11-08
申请号：US11760596
申请日：2007-06-08
申请人： HENNING BOTTCHER , Christian Herhaus , Gerhard Barnickel , Erich Wanker , Volker Heiser , Hans Lehrach , Wolfgang Broecker , Ilona Dunkel
发明人： HENNING BOTTCHER , Christian Herhaus , Gerhard Barnickel , Erich Wanker , Volker Heiser , Hans Lehrach , Wolfgang Broecker , Ilona Dunkel
IPC分类号： A61K31/05 , A61K31/41 , A61K31/42 , A61K31/425 , A61K31/445 , A61K31/47 , A61K31/497 , A61P25/28 , C07D277/82
CPC分类号： A61K31/425 , A61K9/0019 , A61K9/0031 , A61K9/0048 , A61K9/02 , A61K9/06 , A61K9/2018 , A61K9/286 , C07D277/82
摘要： Compounds of formula I, wherein R1, R2, R3, R4 and R5 have the meanings as given in claim 1, and their pharmaceutically tolerable derivatives, solvates and stereoisomers and their use for the preparation of a pharmaceutical for inhibiting the formation of polyQ-aggregation.
摘要翻译：式I的化合物，其中R 1，R 2，R 3，R 4和R 4， 5具有权利要求1中给出的含义及其药学上可耐受的衍生物，溶剂合物和立体异构体及其用于制备抑制聚聚集体形成的药物的用途。

12. 发明申请

US20070059702A1 Disease related protein network 审中-公开
公开(公告)号：US20070059702A1
公开(公告)日：2007-03-15
申请号：US10561669
申请日：2004-06-18
申请人： Erich Wanker , Hans Lehrach , Heike Gohler , Martin Strodicke , Ulrich Stelzl , Maciej Lalowski
发明人： Erich Wanker , Hans Lehrach , Heike Gohler , Martin Strodicke , Ulrich Stelzl , Maciej Lalowski
IPC分类号： C40B40/08 , C40B30/06 , C12Q1/68 , C07H21/04 , C12P21/06 , C07K14/705
CPC分类号： C40B30/04 , C12N15/1055 , G01N33/6896
摘要： The present invention relates to a method for generating a network of direct and indirect interaction partners of a disease-related (poly)peptide comprising the steps of (a) contacting a selection of (poly)peptides suspected to contain one or several of said direct or indirect interaction partners with said disease-related (poly)peptides and optionally with known direct or indirect interaction partners of said disease-related (poly)peptide under conditions that allow the interaction between interaction partners to occur; (b) detecting (poly)peptides that interact with said disease-related (poly)peptide or with said known direct or indirect interaction partners of said disease-related (poly)peptide; (c) contacting (poly)peptides detected in step (b) with a selection of (poly)peptides suspected to contain one or several (poly)peptides interacting with said (poly)peptides detected in step (b) under conditions that allow the interaction between interaction partners to occur; (d) detecting proteins that interact with said (poly)peptides detected in step (b); (e) contacting said disease-related (poly)peptide and optionally said known direct or indirect interaction partners of said disease-related (poly)peptide, said (poly)peptides detected in steps (b) and (d) and a selection of proteins suspected to contain one or several (poly)peptides interacting with any of the afore mentioned (poly)peptides under conditions that allow the interaction between interaction partners to occur; (f) detecting (poly)peptides that interact with said disease-related (poly)peptide and optionally said known direct or indirect interaction partners of said disease-related (poly)peptide or with said (poly)peptides identified in step (b) or (d); and (g) generating a (poly)peptide-(poly)peptide interaction network of said disease-related (poly)peptide and optionally said known direct or indirect interaction partners of said disease-related (poly)peptide and said (poly)peptides identified in steps (b), (d) and (f). Moreover, the present invention relates to a protein complex comprising at least two proteins and to methods for identifying compounds interfering with an interaction of said proteins. Finally, the present invention relates to a pharmaceutical composition and to the use of compounds identified by the present invention for the preparation of a pharmaceutical composition for the treatment of Huntington's disease.

13. 发明授权

US07078191B1 Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation 失效
标题翻译：用于检测与淀粉样样原纤维或蛋白质聚集体形成相关的疾病的组合物和方法
公开(公告)号：US07078191B1
公开(公告)日：2006-07-18
申请号：US09463874
申请日：1998-07-31
申请人： Erich Wanker , Hans Lehrach , Eberhard Scherzinger , Gillian Bates
发明人： Erich Wanker , Hans Lehrach , Eberhard Scherzinger , Gillian Bates
IPC分类号： C12P21/04 , C12N15/00 , C12N1/20 , A01N63/00
CPC分类号： G01N33/6896 , C07K14/4711 , C07K2319/00 , G01N2333/948 , G01N2800/2821
摘要： The present invention relates to novel compositions useful for elucidating the onset or progress of diseases such as Huntington's disease, that are associated with the formation of fibrils or protein aggregates. Further, the present invention relates to methods for monitoring formation of fibrils or protein aggregates as well as to methods for identifying inhibitors of fibril or protein aggregate formation. Additionally, the invention relates to inhibitors of the formation of fibrils or protein aggregates identified by the method of the invention as well as to pharmaceutical compositions that include the inhibitors.
摘要翻译：本发明涉及可用于阐明与形成原纤维或蛋白质聚集体有关的疾病如亨廷顿氏病等发病或进展的新型组合物。此外，本发明涉及用于监测原纤维或蛋白质聚集体的形成的方法以及用于鉴定原纤维或蛋白质聚集体形成抑制剂的方法。此外，本发明涉及通过本发明的方法鉴定的原纤维或蛋白质聚集体形成的抑制剂以及包含抑制剂的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式